Group One Trading’s Keros Therapeutics KROS Stock Holding History

Group One Trading’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-12,100	Closed	-$134K	–	8069
2026 Q1	$134K	Buy	12,100 +11,000	+1,000%	+$170K	﹤0.01%	4462
2025 Q4	$22.4K	Sell	1,100 -85,800	-99%	-$1.51M	﹤0.01%	6266
2025 Q3	$1.37M	Sell	86,900 -24,800	-22%	-$366K	﹤0.01%	2692
2025 Q2	$1.49M	Sell	111,700 -74,600	-40%	-$1.01M	﹤0.01%	2404
2025 Q1	$1.9M	Buy	186,300 +182,200	+4,444%	+$2.12M	0.01%	1860
2024 Q4	$64.9K	Buy	+4,100	New	+$213K	﹤0.01%	4861

Other funds holding KROS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Mackenzie Financial Toronto Ontario, Ontario, Canada $100B AUM 36.93% 1-Year Est. Return

MAP

Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return

Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

Group One Trading's KROS Position: Q2 2026 in Review

Group One Trading reduced its Keros Therapeutics (KROS) stake by 87% in Q2 2026, selling an estimated $7.07K and leaving 99 shares worth $1.06K. The position accounts for ﹤0.01% of the portfolio, ranked #7173.

Group One Trading first reported a position in KROS in Q2 2022 and has held it in 7 quarters since. The position peaked at $506K in Q1 2025. 132 funds tracked by Wall St. Rank hold KROS as of Q2 2026.

Group One Trading held 99 shares of Keros Therapeutics worth $1.06K as of Q2 2026.
Group One Trading sold 635 Keros Therapeutics shares in Q2 2026, an estimated $7.07K.
Keros Therapeutics made up ﹤0.01% of Group One Trading's portfolio in Q2 2026, its #7173 holding.
Group One Trading first reported a position in Keros Therapeutics in Q2 2022 and has held it in 7 quarters since.
Group One Trading's Keros Therapeutics position peaked at $506K in Q1 2025.
132 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2026.

Based on Group One Trading's 13F filing for Q2 2026, filed 14 Aug 2026.